Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Brief description of study

This study will enroll patients who are starting treatment with Zymfentra (infliximab-dyyb) for irritable bowel disease (IBD). This study will collect information about responses to Zymfentra in the “real world” setting. Zymfentra is approved by the United States Food and Drug Administration (FDA) for the treatment of IBD.

Clinical Study Identifier: s25-01094

Principal Investigator: David P Hudesman.

Other Investigators: Elie S Al Kazzi, Shannon Chang, Adam Faye, Simon J Hong, Ariela Holmer, Jordan E Axelrad, Raashi Jain, Lindsay Clarke, Bradley M. Morganstern.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies